Gynatren vaccination is an immunotherapy with Lactobacillus strains.
The killed bacteria contained in the active ingredient stimulate antibody formation against aberrant vaginal germs (deviant vaginal germs) and thus regenerate the disturbed Döderlein flora.
Döderlein bacteria are those lactic acid bacteria that normally colonize the vagina (vagina) of women of childbearing age.
Indications (areas of application)
- Patients with recurrent (recurrent) specific bacterial vaginitis (vaginitis) and trichomoniasis (trichomonad infection).
Contraindications
- Hypersensitivity (allergy) to the antigens and/or phenol contained in Gynatren.
- Acute febrile illness
- Active tuberculosis
- Decompensated heart and kidney disease
- Severe disorders of hematopoiesis (autoimmune and immunoproliferative diseases).
Implementation
- Basic immunization: 3 vaccine doses (3 x 0.5 ml) at intervals of two weeks each.
- Booster vaccination (booster) 6 to 12 months after basic immunizationNote: Booster gynatren is available for booster.
- Vaccination is injected intramuscularly (usually into the deltoid muscle/upper arm muscle).
Efficacy
- After basic immunization, protection occurs for about one year.
- After the first booster vaccination usually provides adequate vaccine protection for at least 2 years; in individual cases longer
- Note: In patients under immunosuppression (suppression of the body’s own defense system) and under radiatio (radiotherapy) it may come to a partial or complete reduction in the effect of gynatren.
Possible side effects/vaccine reactions
- Redness, swelling, burning around the injection site as a local allergic reaction (common, i.e., more than 1 treated in 10)
- Vaccination reactions (general reactions) in the form of fatigue, flu-like symptoms with aching limbs, fever (up to 40 °C) and chills (common)
- Cardiovascular complaints up to circulatory collapse, as well as respiratory problems (very rare cases, i.e., one to 10 treated per 10,000)
Benefits
Vaccination with Gynatren may be considered as an alternative to long-term antibiotic therapy in patients with the above infections.
